218 related articles for article (PubMed ID: 34985313)
1. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-
Galgano SJ; Iravani A; Bodei L; El-Haddad G; Hofman MS; Kong G
AJR Am J Roentgenol; 2022 May; 218(5):767-780. PubMed ID: 34985313
[TBL] [Abstract][Full Text] [Related]
2. Imaging of Small-Bowel Neuroendocrine Neoplasms:
Navin PJ; Ehman EC; Liu JB; Halfdanarson TR; Gupta A; Laghi A; Yoo DC; Carucci LR; Schima W; Sheedy SP
AJR Am J Roentgenol; 2023 Sep; 221(3):289-301. PubMed ID: 36752369
[TBL] [Abstract][Full Text] [Related]
3. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
4. PET/MRI imaging in neuroendocrine neoplasm.
Virarkar MK; Montanarella M; Itani M; Calimano-Ramirez L; Gopireddy D; Bhosale P
Abdom Radiol (NY); 2023 Dec; 48(12):3585-3600. PubMed ID: 36525051
[TBL] [Abstract][Full Text] [Related]
5. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
6. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine Tumors: Diagnostics.
Sakellis C; Jacene HA
PET Clin; 2024 Jul; 19(3):325-339. PubMed ID: 38714399
[TBL] [Abstract][Full Text] [Related]
8. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
Hindié E
Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455
[TBL] [Abstract][Full Text] [Related]
9. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
11. PET/CT and PET/MRI in neuroendocrine neoplasms.
Rajamohan N; Khasawneh H; Singh A; Suman G; Johnson GB; Majumder S; Halfdanarson TR; Goenka AH
Abdom Radiol (NY); 2022 Dec; 47(12):4058-4072. PubMed ID: 35426497
[TBL] [Abstract][Full Text] [Related]
12. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
13. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
14. Partial Response Upon Peptide Receptor Radionuclide Therapy in a Highly Proliferative Pancreatic Neuroendocrine Tumor.
Weich A; Serfling SE; Rowe SP; Solnes LB; Buck AK; Higuchi T; Werner RA
Clin Nucl Med; 2023 Jun; 48(6):547-548. PubMed ID: 36928302
[TBL] [Abstract][Full Text] [Related]
15. [The relevance of PET/CT for the surgical management of neuroendocrine neoplasms].
Hommann M; Kaemmerer D; Hörsch D; Kulkarni HR; Robiller F; Baum RP
Chirurg; 2014 Jun; 85(6):500-4. PubMed ID: 24844432
[TBL] [Abstract][Full Text] [Related]
16. Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI.
Arnfield EG; Tam L; Pattison DA; Younger J; Chikatamarla VA; Wyld D; Burge M; McCormack L; Ladwa R; Ramsay S
J Nucl Cardiol; 2023 Dec; 30(6):2676-2691. PubMed ID: 37587328
[TBL] [Abstract][Full Text] [Related]
17.
Binderup T; Knigge U; Johnbeck CB; Loft A; Berthelsen AK; Oturai P; Mortensen J; Federspiel B; Langer SW; Kjaer A
J Nucl Med; 2021 Jun; 62(6):808-815. PubMed ID: 33067340
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm.
Johnbeck CB; Mortensen J
PET Clin; 2021 Apr; 16(2):191-203. PubMed ID: 33648664
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms.
Iravani A; Parihar AS; Akhurst T; Hicks RJ
Cancer Imaging; 2022 Jun; 22(1):25. PubMed ID: 35659779
[TBL] [Abstract][Full Text] [Related]
20. Limited role of carbidopa-assisted
Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P
Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
